Summary by Moomoo AI
The pharmaceutical company Jeleno-B (HKEX code: 2126) announced that its application for a marketing authorisation for its autologous CAR-T cell immunotherapy product Benoda® (Ricciolense Injection) for the treatment of relapsed or incurable multiple cell lymphoma (r/r MCL) has been accepted by the National Drug Administration of China. The product was approved as a breakthrough therapeutic drug in March 2022 and qualified for priority review in December 2023. This application is based on the results of a critical clinical study showing that Benoda® demonstrated a good clinical response to r/r MCL patients. Dr. Mark J. Gilbert, Chief Medical Officer of Pharmacology, said that Benoda® is expected to be China's first commercialized CAR-T cell product for the treatment of r/r MCL. Pharmacyclo is a biotech company focused on cellular immunotherapy products and aims to be a leader in the field.